394 related articles for article (PubMed ID: 15765621)
1. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
4. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ
Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090
[TBL] [Abstract][Full Text] [Related]
5. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
6. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
[TBL] [Abstract][Full Text] [Related]
7. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine: a new long-acting insulin product.
Reinhart L; Panning CA
Am J Health Syst Pharm; 2002 Apr; 59(7):643-9. PubMed ID: 11944604
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
12. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
14. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
15. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
Hershon KS; Blevins TC; Mayo CA; Rosskamp R
Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
[TBL] [Abstract][Full Text] [Related]
16. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
[TBL] [Abstract][Full Text] [Related]
17. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
20. Insulin glargine.
Gillies PS; Figgitt DP; Lamb HM
Drugs; 2000 Feb; 59(2):253-60; discussion 261-2. PubMed ID: 10730548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
